LYOPHILIZED DRUGS MARKET ANALYSIS

Lyophilized Drugs Market, By Drug Class (Anti-infective, Antineoplastic, Diuretics, Proton Pump Inhibitor, Anesthetic, Anticoagulant, NSAID’s, and Others), By Indication (Oncology, Infectious Disease, Autoimmune Disease, Gastrointestinal Disease, Dermatological Disorders, Respiratory Diseases, Ophthalmic Diseases, Hormonal Disorders, and Others), By Packaging Type (Vial, Injection, and Cartridge), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In January 2023, Berkshire Sterile Manufacturing (BSM), a biotechnology company based in Massachusetts, plans to double its lyophilization capacity by adding a second lyophilizer to its fully automated, isolator-based filling line. This expansion aims to meet increasing demand, allowing them to process up to 70,000 10R vials per run to better serve client needs and patient populations.
In July 2020, Mylan N.V. received regulatory approval from the Drug Controller General of India (DCGI) for its remdesivir lyophilized powder for injection, 100 mg/vial, for restricted emergency use in treating severe COVID-19 cases in India. Marketed under the brand name DESREM, it will be available starting July at INR 4,800 per vial, significantly cheaper than in developed countries.
In September 2021, Lonza invested in additional drug product manufacturing capabilities in Switzerland with a new aseptic flexible filling line at its Stein facility. This line will handle liquid and lyophilized vial filling, cartridges, and pre-filled syringes, accommodating various modalities including monoclonal antibodies and gene therapy products. It will feature state-of-the-art robotic and freeze-drying technology with a sustainable air-cooling system.